ELEVAI Labs Inc. (ELAB) AI Stock Analysis

• Market Cap: $1.57M
• Dividend Yield: N/A
• Average Volume (3M): 781.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 2
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -409.35
• Shares Outstanding: 707,076
• 10 Day Avg. Volume: 1,544,043
• 30 Day Avg. Volume: 781,849
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.63
• Price to Cash Flow (P/CF): -1.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

ELEVAI Labs Inc. faces significant challenges with negative financial performance, adverse technical indicators, and a troubling valuation. Despite a strong equity position, the lack of revenue and negative cash flow highlight operational struggles. The absence of positive catalysts or corporate events directly affecting ELAB further limits the stock's appeal.

ELEVAI Labs Inc. Business Overview & Revenue Model

Company Description

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

How the Company Makes Money

ELEVAI Labs Inc. generates revenue through the sale of its skincare products that leverage exosome technology. The company's revenue streams primarily consist of direct-to-consumer sales through their online platform and partnerships with dermatologists and skincare professionals who incorporate ELEVAI's products into their practice. Additionally, ELEVAI may engage in strategic partnerships with other biotechnology firms or cosmetic companies to expand its market presence and enhance product distribution, thereby contributing to its revenue. The company's focus on innovative biotechnology solutions and targeted marketing efforts are key factors in driving its earnings.

ELEVAI Labs Inc. Financial Statement Overview

Summary

ELEVAI Labs Inc. faces significant challenges in profitability and cash flow generation. The income statement shows instability with declining revenue, indicating difficulties in generating sales. The balance sheet is strong with no debt, but asset management risks exist. Cash flow remains negative, highlighting operational difficulties.

Income Statement

ELEVAI Labs Inc. has struggled with consistent negative operating results, evidenced by a lack of revenue in the latest year and negative EBIT and EBITDA margins. This indicates challenges in generating sales and managing expenses effectively. Although there were revenues in prior years, the trend shows instability with significant decreases in revenue over time.

Balance Sheet

The company maintains a strong equity position with no debt in the latest year, which is a positive indicator of financial stability. However, the equity ratio has fluctuated, reflecting some volatility in asset and liability management. Overall, the balance sheet shows a mix of strengths in equity with potential risks in asset management.

Cash Flow

Cash flow from operations remains negative, indicating ongoing operational challenges. While the company has managed to raise financing, the inability to generate positive free cash flow is concerning. The cash flow metrics suggest difficulties in converting operations into cash, despite improvements in cash reserves over time.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.45M	0.00	1.71M	766.28K	827.00	0.00
	Gross Profit
1.72M	0.00	1.13M	442.27K	-2.02K	0.00
	EBIT
-4.17M	-4.02M	-3.67M	-1.79M	-785.06K	-221.84K
	EBITDA
-4.63M	-4.02M	-4.27M	-1.78M	-782.30K	-1.07K
	Net Income Common Stockholders
-5.47M	0.00	-4.30M	-1.80M	-784.74K	-222.91K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.15M	3.98M	3.33M	1.15M	411.86K	13.35K
	Total Assets
1.89M	8.99M	5.19M	1.89M	666.25K	17.02K
	Total Debt
283.22K	0.00	210.49K	283.22K	0.00	24.00K
	Net Debt
-871.68K	-3.98M	-3.12M	-871.68K	-411.86K	10.65K
	Total Liabilities
760.87K	2.33M	1.36M	760.87K	215.62K	40.61K
	Stockholders Equity
1.13M	6.66M	3.83M	1.13M	450.63K	-23.59K
Cash Flow		Free Cash Flow
-6.05M	-5.49M	-4.57M	-1.62M	-693.41K	-217.16K
	Operating Cash Flow
-5.87M	-5.49M	-4.56M	-1.59M	-660.93K	-217.16K
	Investing Cash Flow
-171.48K	-610.56K	-11.19K	-32.03K	-32.48K	0.00
	Financing Cash Flow
12.00M	6.76M	6.74M	2.36M	1.09M	238.28K

ELEVAI Labs Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAB, the sentiment is Negative. The current price of 2.22 is below the 20-day moving average (MA) of 3.59, below the 50-day MA of 5.96, and below the 200-day MA of 163.59, indicating a bearish trend. The MACD of -1.00 indicates Negative momentum. The RSI at 27.72 is Positive, neither overbought nor oversold. The STOCH value of 14.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELAB.

ELEVAI Labs Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$4.14B	-5.09	-15.20%	5.26%	17.31%	-45.65%
SCNI	52 Neutral	$2.14M	8.23	99.42%	―	―	―
ELAB	37 Underperform	$1.57M	―	-130.35%	―	―	―
ZVSA	29 Underperform	$2.59M	―	-96.10%	―	―	99.39%
PTIX	27 Underperform	$1.62M	―	-236.06%	―	―	-40.51%

ELEVAI Labs Inc. Corporate Events

Northstrive Biosciences Gains FDA Support for EL-22

On April 24, 2025, Northstrive Biosciences Inc. announced receiving positive preliminary responses from the FDA regarding their nonclinical studies and clinical development plans for EL-22, in combination with GLP-1 receptor agonists, aimed at treating obesity. The FDA’s feedback supports Northstrive’s plan to file an IND application for a Phase 2 clinical trial, marking a significant milestone in addressing the challenge of muscle preservation in obesity treatments, with ongoing preparations for production of EL-22.

Spark’s Take on ELAB Stock

According to Spark, TipRanks’ AI Analyst, ELAB is a Underperform.

ELEVAI Labs Inc.’s stock score is significantly impacted by its poor financial performance, characterized by negative revenue and cash flow. The adverse technical indicators further emphasize the stock’s downward trajectory. Additionally, valuation concerns with a negative P/E ratio contribute to a lower score. Despite positive industry news, these do not directly influence ELEVAI Labs Inc., leaving the corporate events factor out of consideration.

To see Spark’s full report on ELAB stock, click here.

PMGC Holdings Announces Acquisition of IT Packaging Firm

On April 16, 2025, PMGC Holdings Inc. announced the signing of a non-binding Letter of Intent to acquire a profitable U.S.-based custom IT packaging company. This target company, founded in 2011 and headquartered in Southern California, serves over 300 commercial clients with a strong U.S.-based revenue stream and has a reputation for reliability and service quality. The acquisition marks the launch of PMGC’s acquisition strategy, aiming to expand through acquiring profitable businesses with strong fundamentals. The transaction is expected to be completed by the end of Q2 2025, with the target company operating as a wholly owned subsidiary, maintaining its current operations team.

Spark’s Take on ELAB Stock

According to Spark, TipRanks’ AI Analyst, ELAB is a Underperform.

ELEVAI Labs Inc. faces major challenges in financial performance with negative revenue trends and cash flow issues, which heavily impacts its score. Technical analysis also indicates a negative trajectory, with the stock trading well below key moving averages. Valuation concerns arise from a negative P/E ratio and lack of dividend yield. Despite positive corporate events, these are not directly attributable to ELEVAI Labs Inc., thereby not influencing the score.

To see Spark’s full report on ELAB stock, click here.

ELEVAI Labs Inc. Considers Further Share Repurchases

On March 18, 2025, PMGC Holdings Inc. repurchased shares from existing shareholders who directly contacted the company, with the transaction closing on the same day. The company announced on March 21, 2025, that it may consider further repurchases from other investors, depending on market conditions, but it is not conducting a formal share repurchase program.

ELEVAI Labs Inc. Ends License Agreement with INmune

PMGC Holdings Inc. had previously entered into a License Agreement with INmune Bio, Inc. to develop, manufacture, and commercialize INmune’s EMx technology for topical cosmetic products in the medical aesthetics skincare market. On February 27, 2025, PMGC Holdings and INmune mutually terminated this agreement, with no further fees due to INmune. PMGC Holdings is considering other biotechnology assets from INmune but has not made any decisions.

Northstrive Biosciences Submits Pre-IND Request for EL-22

On February 18, 2025, Northstrive Biosciences announced the successful submission of a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration for EL-22, a pioneering obesity therapy aimed at fat loss and muscle preservation. The company is seeking FDA guidance on its nonclinical studies and clinical development plans for combining EL-22 with GLP-1 receptor agonists, with a meeting expected in the second fiscal quarter of 2025. This development could significantly impact Northstrive’s market positioning as it lays the groundwork for further clinical trials necessary for EL-22’s regulatory approval and commercial availability.

Northstrive Biosciences Unveils Innovative Obesity Drug Candidates

On February 7, 2025, Northstrive Biosciences presented its innovative obesity drug candidates, EL-22 and EL-32, at the UCLA Obesity Symposium. These drugs are designed to preserve muscle mass during weight loss, addressing a major concern with current obesity treatments. The presentation highlighted the unique mechanism of EL-22, which uses engineered probiotics to stimulate myostatin-specific immune responses, potentially revolutionizing treatments in the obesity sector.